Patrick Deval L - Nov 1, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Nov 1, 2023
Transactions value $: -$373,009
Form type: 4
Date filed: 11/3/2023, 04:15 PM
Previous filing: Sep 19, 2023
Next filing: Dec 19, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$380K	+30.1K	+918.04%	$12.62	33.4K	Nov 1, 2023	Direct	F1, F2
transaction	CERE	Common Stock	Sale	-$753K	-30.1K	-90.18%	$25.00	3.28K	Nov 1, 2023	Direct	F1, F2

Showing 1 to 2 of 2 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-30.1K	-70.59%	$0.00	12.6K	Nov 1, 2023	Common Stock	30.1K	$12.62	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person.
F2	Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan that were previously reported by the Reporting Person.
F3	This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021.